MEDI-CAPS LIMITED
Regd. Office and works:
Mhow - Neemuch Road, Sector 1, CIN: L70100MP1983PLC002231
Pithampur - 454775, Dist. Dhar
Madhya Pradesh, India
Ph:- 07292-256205
Fax:- 0731-4041435
E mail:- **investors@medicaps.com**
Website:- **www.medicaps.com**

MCL/SE/2022-2023 **Date: 09th February, 2023**

Online filing at: **www.listing.bseindia.com**

To,
The General Manager
DCS-CRD
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street Fort, Mumbai – 400001 (M.H.)

Subject: Submission of the Standalone and Consolidated Un-audited Financial Results for the Quarter and Nine Months ended on 31st December, 2022 in terms of Regulation 33 of SEBI (LODR) Regulations, 2015.
Ref: MEDI-CAPS LIMITED (BSE Scrip Code: 523144, ISIN: INE442D01010)

Dear Sir/Madam,

This is in Continuation of our letter no. MCL/BM/SE/2022-2023 dated 01st February, 2023 regarding information of Board Meeting for consideration and approval of Standalone as well as Consolidated Un-Audited Financial Results for the Quarter and Nine months ended on 31st December, 2022.

In compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to submit the Un-audited Standalone and Consolidated Financial Results for the quarter and nine months ended 31st December, 2022 duly approved by the Board at its meeting held today i.e.09th February, 2023 along with Limited Review Report given by the Statutory Auditors of the Company, as required under the above said Regulations.

Further, copy of Un-Audited Financial Results shall also be submitted in XBRL mode within 24 hours from the conclusion of Board Meeting.

The aforesaid results will be uploaded on the Company's website www.medicaps.com and on the website of the Stock Exchange at www.bseindia.com. Further the extracts of aforesaid results will be published in Hindi (vernacular) and widely circulated English Newspaper.

You are requested to please take on record the aforesaid Results for your records and reference.

Thanking You,
Yours Faithfully,
FOR, MEDI-CAPS LIMITED

ALOK KUMAR GARG
Digitally signed by ALOK KUMAR GARG
Date: 2023.02.09 16:20:26 +05'30'

ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321

Encl.: Unaudited Standalone and Consolidated Financial Results along with limited review report for quarter and nine months ended 31st December, 2022;

RAWKA & ASSOCIATES

CHARTERED ACCOUNTANTS
412, Arcade Silver 56, 1, New Palasia, Indore - 1
☎ Off. : 2541132, Mobile : 9039080380
E-mail : rawkaassociates@gmail.com,. cprawka@gmail.com

<u>Independent Auditors' Review Report on Standalone Unaudited Quarterly and year to date Financial Results of Medi-Caps Limited ('the Company') pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended</u>

To,
THE BOARD OF DIRECTORS OF
MEDI-CAPS LIMITED

1. We have reviewed the accompanying statement of unaudited standalone financial results ("the Statement") of MEDI-CAPS LIMITED ("the Company") for the quarter and Nine months ended December 31, 2022 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations'), including relevant circulars issued by the SEBI from time to time.

2. The Statement is the responsibility of the Company's Management and has been approved by the Company's Board of Directors. Our responsibility is to issue a report on the Statement based on our review of the Statement, which has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), specified under Section 133 of the Companies Act, 2013 read with relevant rules issued there under, and other accounting principles generally accepted in India and in Compliance with Regulation 33 of the Listing Regulations.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in the applicable Indian accounting standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

Date: 09.02.2023
Place: Indore
UDIN: **23429040BGXBCS7528**

For, Rawka & Associates
(Chartered Accountants)
FRN 021606C

RAWKA ASSOCIATES INDORE (M.P.) Chartered Accountants

Venus Rawka
(Partner)
M. No. 429040

MEDI-CAPS LIMITED

REGD. OFFICE: MHOW-NEEMUCH ROAD, SECTOR-1,PITHAMPUR-454775, DISTT. DHAR (M.P.), Tel: 07292-256205, Fax: 0731-4041435

Website: www.medicaps.com **Email:** investors@medicaps.com **CIN:** L70100MP1983PLC002231

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER 2022

(Amount in Lakhs except EPS)

S.N.	Particulars	Quarter Ended			Nine Month Ended		Year Ended
		3 Month Ended	Preceeding 3 Month Ended	Corresponding 3 months ended	Year to date figures for current period	Year to date figures for the previous	Previous Year ended M

(ii) Income tax on items that will be reclassified to statement of P&L	0.00	0.00	0.00	0.00	0.00	0.00

RAWKA & ASSOCIATES
CHARTERED ACCOUNTANTS
412, Arcade Silver 56, 1, New Palasia, Indore - 1
☎ Off. : 2541132, Mobile : 9039080380
E-mail : rawkaassociates@gmail.com,. cprawka@gmail.com

Independent Auditor's Review Report On Consolidated Unaudited Quarterly and year to date Financial Results of Medi-Caps Limited (the Parent Company) Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

To,
THE BOARD OF DIRECTORS OF
MEDI-CAPS LIMITED

1. We have reviewed the accompanying Statement of the Consolidated Unaudited Financial Results ("the Statement") of Medi-Caps Limited ("the Parent Company") and its subsidiary (the Parent and its subsidiary together referred to as "the Group"), and its share of the net profit after tax and total comprehensive profit for the quarter and Nine month ended December 31, 2022, being submitted by the Parent Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Listing Regulations'), including relevant circular issued by the SEBI time to time.

2. This Statement, which is the responsibility of the Parent Company's Management and approved by the Parent Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

RAWKA & ASSOCIATES
INDORE (M.P.)
Chartered Accountants

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of its wholly owned subsidiary Medgel Private Limited.

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the information and explanations given to us by the Parent Company's Management , nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be

	Other Comprehensive Income for the period	**-80.60**	**240.19**	**178.07**	**171.14**	**980.66**	**1154.35**
XVIII	Profit or Loss Attributable to						
	Profit or Loss Attributable to owners of Parents	**-133.76**	**214.26**	**204.93**	**139.37**	**858.45**	**1008.03**
	Profit or Loss Attributable to non-Controlling Interest	0.00	0.00	0.00	0.00	0.00	0.00
XIX	Total Comprehensive Income for the period Attributable to						
	Total Comprehensive Income for the period Attributable to owners of Parents	**-80.60**	**240.19**	**178.07**	**171.14**	**980.66**	**1154.35**
	Total Comprehensive Income for the period Attributable to non-Controlling Interest	0.00	0.00	0.00	0.00	0.00	0.00
XX	Paid-up equity share capital of the company	1247.00	1247.00	1247.00	1247.00	1247.00	1247.00
XXII	Earnings per equity share (for continuing operation)						
	a) Basic (Rs.)	(1.04)	1.73	1.67	1.20	6.89	8.05
	b) Diluted (Rs.)	(1.04)	1.73	1.67	1.20	6.89	8.05
	Earnings per equity share (for discontinued operation)						
	a) Basic (Rs.)	(0.03)	(0.01)	(0.03)	(0.08)	0.00	0.03
	b) Diluted (Rs.)	(0.03)	(0.01)	(0.03)	(0.08)	0.00	0.03
	Earnings per equity share (for discontinued and continuing operation)						
	a) Basic (Rs.)	(1.07)	1.72	1.64	1.12	6.89	8.08
	b) Diluted (Rs.)	(1.07)	1.72	1.64	1.12	6.89	8.08

DATE: 09.02.2023
PLACE: INDORE

MEDI-CAPS LIMITED ★ INDORE ★

For and on behalf of board of directors of
MEDI-CAPS LIMITED

ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321

MEDI-CAPS LIMITED

Website: www.medicaps.com **Email:** investors@medicaps.com **CIN:** L70100MP1983PLC002231

Consolidated Segment Revenue, Results and Capital Employed for Quarter and Nine Months ended 31st December, 2022

(Amount in Lakhs)

S.No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		3 Month Ended 31/12/2022	3 Month Ended 30/09/2022	Corresponding 3 months ended in the previous year 31/12/2021	Year to date figures for current period ended 31/12/2022	Year to date figures for the previous year ended 31/12/2021	Previous Year ended March 31 2022
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
	Segment Revenue						
	Pharma Division	1,119.41	1,565.32	1,756.16	3,950.89	5,232.15	7,117.80
	Real Estate Division	1.36	61.81	43.52	65.79	46.43	60.74
	Other	0.00	0.00	0.00	0.00	0.00	0.00

NOTES:

1. The above Un-audited Financial Results for the Quarter as well as Nine Months ended December 31, 2022 have been reviewed by the Audit Committee and subsequently approved by the Board of Directors in their meeting held on February 09, 2023. The above results have been reviewed by statutory Auditors of the company in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 who have expressed an unmodified opinion. The Company's Management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of its affairs.

... financial results have been prepared in accordance with the